Morphic Holding, Inc. (MORF): Price and Financial Metrics


Morphic Holding, Inc. (MORF)

Today's Latest Price: $26.24 USD

0.58 (-2.16%)

Updated Oct 28 11:08am

Add MORF to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

MORF Stock Summary

  • MORF's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.21 -- higher than merely 4.06% of US-listed equities with positive expected earnings growth.
  • MORF's went public 1.34 years ago, making it older than only 1.09% of listed US stocks we're tracking.
  • The ratio of debt to operating expenses for Morphic Holding Inc is higher than it is for about only 0.35% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Morphic Holding Inc, a group of peers worth examining would be MGNX, VBLT, CRBP, FIXX, and CARA.
  • Visit MORF's SEC page to see the company's official filings. To visit the company's web site, go to www.morphictx.com.

MORF Stock Price Chart Interactive Chart >

Price chart for MORF

MORF Price/Volume Stats

Current price $26.24 52-week high $31.00
Prev. close $26.82 52-week low $9.90
Day low $26.00 Volume 8,816
Day high $26.24 Avg. volume 83,544
50-day MA $26.78 Dividend yield N/A
200-day MA $21.37 Market Cap 804.47M

Morphic Holding, Inc. (MORF) Company Bio


Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.


MORF Latest News Stream


Event/Time News Detail
Loading, please wait...

MORF Latest Social Stream


Loading social stream, please wait...

View Full MORF Social Stream

Latest MORF News From Around the Web

Below are the latest news stories about Morphic Holding Inc that investors may wish to consider to help them evaluate MORF as an investment opportunity.

Morphic Holding (MORF) Investor Presentation - Slideshow

The following slide deck was published by Morphic Holding, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 15, 2020

AbbVie opts in to develop fibrotic disease candidates with Morphic

Morphic Therapeutic (MORF) announces that collaboration partner and licensee AbbVie (ABBV) has exercised its option to develop its αvβ6 integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis ((IPF)) and additional indications.The license covers αvβ6 integrin specific inhibitors discovered from Morphic’s proprietary MInT Platform, including the compounds MORF-720 and...

Seeking Alpha | August 25, 2020

Morphic Therapeutic Presents Positive Preclinical Data Supporting Development of MORF-057 in Inflammatory Bowel Disease at Digestive Disease Week 2020

Receptor occupancy, potency and selectivity data further build MORF-057 preclinical profile as an oral small molecule treatment candidate for IBD IND filing on track for.

Yahoo | June 29, 2020

Morphic to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference

Morphic Therapeutic (MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer, and Marc Schegerin, M.D., chief financial officer and chief operating officer, are scheduled to make a presentation at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference at 11:00 a.m. ET on Tuesday, June 23, 2020. Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer.

Yahoo | June 18, 2020

Hedge Funds Nibbling On Morphic Holding, Inc. (MORF)

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]

Yahoo | June 16, 2020

Read More 'MORF' Stories Here

MORF Price Returns

1-mo -2.45%
3-mo 6.45%
6-mo 102.00%
1-year 77.78%
3-year N/A
5-year N/A
YTD 52.91%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6554 seconds.